Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice

Peptides

Volumn 29, Issue 8, 2008, Pages 1347-1353

  Yu, Rongjie ^a   Yi, Tianhong ^a   Xie, Shanshan ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Glucose; Insulin; Maxadilan; PAC1; PACAP

Indexed keywords

GLUCOSE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; INSULIN; LOW DENSITY LIPOPROTEIN; MAXADILAN; PROTEIN INHIBITOR; PROTEIN M65; PROTEIN PAC1 RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; UPREGULATION;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EATING; HOMEOSTASIS; HYPERGLYCEMIA; INSECT PROTEINS; INSULIN; INSULIN RESISTANCE; MALE; MICE; PEPTIDE FRAGMENTS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECOMBINANT PROTEINS; TIME;

MUS;

EID: 47649116440     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.03.017     Document Type: Article

References (27)

1. Akesson L., Ahrén B., Manganiello V.C., Holst L.S., Edgren G., and Degerman E. Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology 144 12 (2003) 5293-5299
2. Borboni P., Porzio O., Pierucci D., Cicconi S., Magnaterra R., Federici M., et al. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory system. Endocrinology 140 12 (Dec 1999) 5530-5537
3. Chatterjee T.K., Sharma R.V., and Fisher R.A. Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 271 50 (1996) 32226-32232
4. Filipsson K., Holst J.J., and Ahrén B. PACAP contributes to insulin secretion after gastric glucose gavage in mice. Am J Physiol Regul Integr Comp Physiol 279 August (2) (2000) R424-R432
5. Gray S.L., Cummings K.J., Jirik F.R., and Sherwood N.M. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15 10 (2001) 1739-1747
6. Green B.D., Irwin N., Cassidy R.S., Gault V.A., and Flatt P.R. Long-term administration of PACAP receptor antagonist, PACAP (6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice. Peptides 27 9 (2006) 2343-2349
7. Green B.D., Irwin N., and Flatt P.R. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides 27 6 (2006) 1349-1358
8. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 June (2) (1998) 265-270
9. Jamen F., Persson K., Bertrand G., Rodriguez-Henche N., Puech R., Bockaert J., et al. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105 9 (2000) 1307-1315
10. Lerner E.A., Iuga A.O., and Reddy V.B. Maxadilan, a PAC1 receptor agonist from sand flies. Peptides 28 9 (2007) 1651-1654
11. Lerner E.A., Ribeiro J.M., Nelson R.J., and Lerner M.R. Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. J Biol Chem 266 June 15 (17) (1991) 11234-11236
12. Mizuno Y., Kondo K., Terashima Y., Arima H., Murase T., and Oiso Y. Anorectic effect of pituitary adenylate cyclase activating polypeptide (PACAP) in rats: lack of evidence for involvement of hypothalamic neuropeptide gene expression. J Neuroendocrinol 10 (1998) 611-616
13. Moro O., and Lerner E.A. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 272 2 (1997) 966-970
14. Moro O., Wakita K., Ohnuma M., Denda S., Lerner E.A., and Tajima M. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem 274 33 (1999) 23103-23110
15. Nakata M., Shioda S., Oka Y., Maruyama I., and Yada T. Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cells. Peptides 20 8 (1999) 943-948
16. Pereira P., Reddy V.B., Kounga K., Bello Y., and Lerner E. Maxadilan activates PAC1 receptors expressed in Xenopus laevis melanophores. Pigment Cell Res 15 6 (2002) 461-466
17. Reddy V.B., Iuga A.O., Kounga K., and Lerner E.A. Functional analysis of recombinant mutants of maxadilan with a PAC1 receptor-expressing melanophore cell line. J Biol Chem 281 24 (2006) 16197-16201
18. Sekiguchi Y., Kasai K., Hasegawa K., Suzuki Y., and Shimoda S. Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro. Life Sci 55 15 (1994) 1219-1228
19. Sherwood N.M., Krueckl S.L., and McRory J.E. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21 6 (2000) 619-670
20. Tachibana T., Saito E.S., Tomonaga S., Takagi T., Saito E., Boswell T., et al. Intracerebroventricular injection of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibits feeding in the chick. Neurosci Lett 339 (2003) 203-206
21. Uchida D., Tatsuno I., Tanaka T., Hirai A., Saito Y., Moro O., et al. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. Ann N Y Acad Sci December 11 (865) (1998) 253-258
22. Yada T., Sakurada M., Filipsson K., Kikuchi M., and Ahrén B. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci 921 (2000) 259-263
23. Yada T., Sakurada M., Ishihara H., Nakata M., Shioda S., Yaekura K., et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol 505 Pt 2 (1997) 319-328
24. 2+ responses to sub-picomolar and nanomolar PACAP in pancreatic betacells are mediated by VPAC2 and PAC1 receptors. Regul Pept 123 1-3 (2004) 147-153
25. Yamamoto K., Hashimoto H., Tomimoto S., Shintani N., Miyazaki J., Tashiro F., et al. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52 5 (2003) 1155-1162
26. Yokota C., Kawai K., Ohashi S., Watanabe Y., and Yamashita K. PACAP stimulates glucose output from the perfused rat liver. Peptides 16 1 (1995) 55-60
27. Yu R.J., Xie Q.L., Dai Y., Gao Y., Zhou T.H., and Hong A. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides 27 June (6) (2006) 1359-1366 [Epub 2006 February 24]